These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9189213)

  • 1. Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing.
    Rose DN; Sacks HS
    AIDS; 1997 Jun; 11(7):883-7. PubMed ID: 9189213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection.
    Paltiel AD; Scharfstein JA; Seage GR; Losina E; Goldie SJ; Weinstein MC; Craven DE; Freedberg KA
    Med Decis Making; 1998; 18(2 Suppl):S93-105. PubMed ID: 9566470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis.
    Moore RD; Chaisson RE
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Sep; 16(1):15-21. PubMed ID: 9377120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of preventing AIDS-related opportunistic infections.
    Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
    JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus.
    Paltiel AD; Goldie SJ; Losina E; Weinstein MC; Seage GR; Kimmel AD; Zhang H; Freedberg KA
    Clin Infect Dis; 2001 Mar; 32(5):783-93. PubMed ID: 11229847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice.
    Mauskopf JA; Richter A; Annemans L; Maclaine G
    Pharmacoeconomics; 2000 Sep; 18(3):239-51. PubMed ID: 11147391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
    Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
    Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response of asymptomatic cytomegalovirus viraemia to oral ganciclovir 3 g/day or 6 g/day in HIV-infected patients.
    Grzywacz M; Deayton JR; Bowen EF; Wilson P; Emery VC; Johnson MA; Griffiths PD
    J Med Virol; 1999 Nov; 59(3):323-8. PubMed ID: 10502264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incremental cost-effectiveness analysis of intravenous ganciclovir versus oral ganciclovir in the maintenance treatment of newly diagnosed cytomegalovirus retinitis in patients with AIDS.
    Rachlis A; Smaill F; Walker V; Hotchkies L; Jones A
    Pharmacoeconomics; 1999 Jul; 16(1):71-84. PubMed ID: 10539123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group.
    Spector SA; McKinley GF; Lalezari JP; Samo T; Andruczk R; Follansbee S; Sparti PD; Havlir DV; Simpson G; Buhles W; Wong R; Stempien M
    N Engl J Med; 1996 Jun; 334(23):1491-7. PubMed ID: 8618603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The evaluation of cost-effectiveness and cost-utility of valganciclovir for the prophylaxis of cytomegalovirus disease to 200 days after kidney transplantation].
    Kawalec P; Holko P; Szkultecka-Debek M; Paszulewicz A; Boratyńska M; Głyda M; Ignacak E; Maks J; Russel-Szymczyk M; Kaweczyńska-Lasoń A
    Pol Merkur Lekarski; 2013 Jun; 34(204):332-8. PubMed ID: 23882930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost advantages of oral drug therapy for managing cytomegalovirus disease.
    Somerville KT
    Am J Health Syst Pharm; 2003 Dec; 60(23 Suppl 8):S9-12. PubMed ID: 14686229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged prophylaxis with valganciclovir is cost effective in reducing posttransplant cytomegalovirus disease within the United States.
    Blumberg EA; Hauser IA; Stanisic S; Mueller E; Berenson K; Gahlemann CG; Humar A; Jardine AG
    Transplantation; 2010 Dec; 90(12):1420-6. PubMed ID: 21063245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. Terry Beirn Community Programs for Clinical Research on AIDS.
    Brosgart CL; Louis TA; Hillman DW; Craig CP; Alston B; Fisher E; Abrams DI; Luskin-Hawk RL; Sampson JH; Ward DJ; Thompson MA; Torres RA
    AIDS; 1998 Feb; 12(3):269-77. PubMed ID: 9517989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost of prophylaxis in the management of cytomegalovirus infection in solid organ transplant recipients.
    Oppenheimer F; Gonzalez-Molina M; Rubio M
    Clin Transplant; 2007; 21(4):441-8. PubMed ID: 17645702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation.
    Speich R; Thurnheer R; Gaspert A; Weder W; Boehler A
    Transplantation; 1999 Jan; 67(2):315-20. PubMed ID: 10075601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
    Shah T; Lai WK; Mutimer D
    Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral ganciclovir fails to prevent CMV in HIV trial.
    McCarthy M
    Lancet; 1995 Sep; 346(8979):895. PubMed ID: 7564679
    [No Abstract]   [Full Text] [Related]  

  • 19. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.
    Laurenti L; Piccioni P; Cattani P; Cingolani A; Efremov D; Chiusolo P; Tarnani M; Fadda G; Sica S; Leone G
    Haematologica; 2004 Oct; 89(10):1248-52. PubMed ID: 15477211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An economic cost analysis of oral ganciclovir prophylaxis for the prevention of CMV disease.
    Liu GG; Hay J
    Pharm Res; 2000 Aug; 17(8):911-9. PubMed ID: 11028934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.